{
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "YqrH0G07nYKk"
      },
      "source": [
        "Preprocessing"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 1,
      "metadata": {
        "id": "-nTHcHOgxoV4"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "\n",
            "\u001b[1m[\u001b[0m\u001b[34;49mnotice\u001b[0m\u001b[1;39;49m]\u001b[0m\u001b[39;49m A new release of pip is available: \u001b[0m\u001b[31;49m25.1.1\u001b[0m\u001b[39;49m -> \u001b[0m\u001b[32;49m25.2\u001b[0m\n",
            "\u001b[1m[\u001b[0m\u001b[34;49mnotice\u001b[0m\u001b[1;39;49m]\u001b[0m\u001b[39;49m To update, run: \u001b[0m\u001b[32;49mpip install --upgrade pip\u001b[0m\n"
          ]
        }
      ],
      "source": [
        "!pip3 install -qU bs4 tiktoken openai langchain langchain-community pinecone pypdf tqdm dotenv"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "ksVMdUysRY95"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "OpenAI API Key: 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\n"
          ]
        }
      ],
      "source": [
        "import os\n",
        "from dotenv import load_dotenv\n",
        "load_dotenv()\n",
        "\n",
        "openai_api_key = os.getenv(\"OPENAI_API_KEY\")\n",
        "pinecone_api_key = os.getenv(\"PINECONE_API_KEY\")\n",
        "\n",
        "pdf_folder_path = \"references/\" #clinical document location"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 123,
      "metadata": {
        "id": "8MMxrndhQTZ-"
      },
      "outputs": [
        {
          "name": "stderr",
          "output_type": "stream",
          "text": [
            "Ignoring wrong pointing object 6 0 (offset 0)\n",
            "Ignoring wrong pointing object 11 0 (offset 0)\n",
            "Ignoring wrong pointing object 17 0 (offset 0)\n",
            "Ignoring wrong pointing object 6 0 (offset 0)\n",
            "Ignoring wrong pointing object 8 0 (offset 0)\n",
            "Ignoring wrong pointing object 10 0 (offset 0)\n",
            "Ignoring wrong pointing object 12 0 (offset 0)\n"
          ]
        }
      ],
      "source": [
        "from langchain.document_loaders import PyPDFDirectoryLoader\n",
        "loader = PyPDFDirectoryLoader(pdf_folder_path)\n",
        "dataset = loader.load()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 124,
      "metadata": {
        "id": "2H2bsyVT0ClM"
      },
      "outputs": [],
      "source": [
        "data = []\n",
        "\n",
        "for doc in dataset:\n",
        "    data.append({\n",
        "        'reference': doc.metadata['source'].replace('rtdocs/', 'https://'),\n",
        "        'text': doc.page_content\n",
        "    })"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 125,
      "metadata": {
        "id": "nWXruhm5S5SQ"
      },
      "outputs": [],
      "source": [
        "import tiktoken\n",
        "\n",
        "tokenizer = tiktoken.get_encoding('cl100k_base')\n",
        "\n",
        "# create the length function\n",
        "def tiktoken_len(text):\n",
        "    tokens = tokenizer.encode(\n",
        "        text,\n",
        "        disallowed_special=()\n",
        "    )\n",
        "    return len(tokens)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 126,
      "metadata": {
        "id": "2FCYmaKGS87y"
      },
      "outputs": [],
      "source": [
        "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
        "\n",
        "text_splitter = RecursiveCharacterTextSplitter(\n",
        "    chunk_size=1000,\n",
        "    chunk_overlap=100,\n",
        "    length_function=tiktoken_len,\n",
        "    separators=[\"\\n\\n\", \"\\n\", \" \", \"\"]\n",
        ")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 127,
      "metadata": {
        "id": "o-PQwiN1TXF0"
      },
      "outputs": [
        {
          "name": "stderr",
          "output_type": "stream",
          "text": [
            "100%|██████████| 278/278 [00:00<00:00, 928.58it/s] \n"
          ]
        }
      ],
      "source": [
        "from uuid import uuid4\n",
        "from tqdm.auto import tqdm\n",
        "\n",
        "chunks = []\n",
        "\n",
        "for idx, record in enumerate(tqdm(data)):\n",
        "    texts = text_splitter.split_text(record['text'])\n",
        "    chunks.extend([{\n",
        "        'id': str(uuid4()),\n",
        "        'text': texts[i],\n",
        "        'chunk': i,\n",
        "        'reference': record['reference']\n",
        "    } for i in range(len(texts))])"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "JhaAONVNTmxX"
      },
      "source": [
        "Embedding Model"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "8pq7s6XcTkdW"
      },
      "outputs": [],
      "source": [
        "import openai\n",
        "\n",
        "embed_model = \"text-embedding-3-small\""
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "ZOpzgtL_nezR"
      },
      "source": [
        "Vector Storage"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "xcPrqVIiTql5"
      },
      "outputs": [
        {
          "data": {
            "text/plain": [
              "{'dimension': 1536,\n",
              " 'index_fullness': 0.0,\n",
              " 'metric': 'cosine',\n",
              " 'namespaces': {'': {'vector_count': 896}},\n",
              " 'total_vector_count': 896,\n",
              " 'vector_type': 'dense'}"
            ]
          },
          "execution_count": 129,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "from pinecone import Pinecone\n",
        "from pinecone import ServerlessSpec\n",
        "\n",
        "pc = Pinecone(\n",
        "    api_key=pinecone_api_key, #Pinecone API\n",
        "    # environment=\"gcp-starter\"\n",
        ")\n",
        "index_name = \"preopai-index-py\"\n",
        "\n",
        "if not pc.has_index(index_name):\n",
        "    pc.create_index(\n",
        "        name=index_name,\n",
        "        vector_type=\"dense\",\n",
        "        dimension=1536,\n",
        "        metric=\"cosine\",\n",
        "        spec=ServerlessSpec(\n",
        "            cloud=\"aws\",\n",
        "            region=\"us-east-1\"\n",
        "        ),\n",
        "    )\n",
        "\n",
        "index = pc.Index(index_name)\n",
        "index.describe_index_stats()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "ATElJYPCT8Cx"
      },
      "outputs": [
        {
          "name": "stderr",
          "output_type": "stream",
          "text": [
            "100%|██████████| 5/5 [00:19<00:00,  3.90s/it]\n"
          ]
        }
      ],
      "source": [
        "from tqdm.auto import tqdm\n",
        "import datetime\n",
        "from time import sleep\n",
        "from openai import OpenAI\n",
        "client = OpenAI(api_key=openai_api_key)\n",
        "\n",
        "batch_size = 100\n",
        "\n",
        "for i in tqdm(range(0, len(chunks), batch_size)):\n",
        "    i_end = min(len(chunks), i+batch_size)\n",
        "    meta_batch = chunks[i:i_end]\n",
        "    ids_batch = [x['id'] for x in meta_batch]\n",
        "    texts = [x['text'] for x in meta_batch]\n",
        "    try:\n",
        "        res = client.embeddings.create(input=texts, model=embed_model)\n",
        "    except:\n",
        "        done = False\n",
        "        while not done:\n",
        "            sleep(5)\n",
        "            try:\n",
        "                res = client.embeddings.create(input=texts, model=embed_model)\n",
        "                done = True\n",
        "            except:\n",
        "                pass\n",
        "    embeds = [record.embedding for record in res.data]\n",
        "    meta_batch = [{\n",
        "        'text': x['text'],\n",
        "        'chunk': x['chunk'],\n",
        "        'reference': x['reference']\n",
        "    } for x in meta_batch]\n",
        "    to_upsert = list(zip(ids_batch, embeds, meta_batch))\n",
        "    index.upsert(vectors=to_upsert)"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "0qqJl4zhUKOD"
      },
      "source": [
        "Retrieval Agent"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "SCtzC1vGUIGo"
      },
      "outputs": [
        {
          "data": {
            "text/plain": [
              "{'dimension': 1536,\n",
              " 'index_fullness': 0.0,\n",
              " 'metric': 'cosine',\n",
              " 'namespaces': {'': {'vector_count': 896}},\n",
              " 'total_vector_count': 896,\n",
              " 'vector_type': 'dense'}"
            ]
          },
          "execution_count": 131,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "from pinecone import Pinecone\n",
        "\n",
        "pc = Pinecone(\n",
        "    api_key=pinecone_api_key, #Pinecone API\n",
        "    # environment=\"gcp-starter\"\n",
        ")\n",
        "index_name = \"preopai-index-py\"\n",
        "\n",
        "index = pc.Index(index_name)\n",
        "index.describe_index_stats()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "4UmChHaJURTi"
      },
      "outputs": [],
      "source": [
        "from openai import OpenAI\n",
        "client = OpenAI()\n",
        "\n",
        "query = str(\"38/Chinese/Female\\\n",
        "Allergy to aspirin, paracetamol, penicillin - rashes and itchiness \\\n",
        "ExSmoker—smoked 10 years ago/Occasional Drinker \\\n",
        "LMP: last month\\\n",
        "Wt 94.7 Ht 166.3 BMI 34.2 BP 127/81 HR 88 SpO2 100% on RA \\\n",
        "Coming in for BILATERAL REVISION FESS, REVISION SEPTOPLASTY, ADENOIDECTOMY, AND BILATERAL INFERIOR TURBINOPLASTIES/SEVERE OSA ON CPAP \\\n",
        "=== PAST MEDICAL HISTORY ===\\\n",
        "1. Severe OSA on CPAP—AHI 58—CPAP settings: AutoCPAP (4–15) cmH2O, without humidifier/Chinstrap\\\n",
        "2. Right persistent Sinusitis\\\n",
        "3. Allergic rhinitis\\\n",
        "4. Adenoid hypertrophy\\\n",
        "5. High BMI\\\n",
        "6. Asthma—f/u GP, last seen 3 months ago for attack—on PRN ventolin—Does not use ventolin at all—No previous admissions/ intubations for asthma\\\n",
        "7. Diabetes—HbA1C 9.4%, Last seen outpatient doctor >1 year ago.\\\n",
        "No history of HTN/ HLD/ IHD/ CVA\\\n",
        "=== SURGICAL HISTORY===\\\n",
        "Tonsillectomy > 10 years ago mild PONV\\\n",
        "===Investigations===\\\n",
        "Hb 13.0 TW 4 Plt 392\\\n",
        "INR PT APTT normal\\\n",
        "Na 134 K3.4 Cr 77 Glu 13\\\n",
        "ECG NSR\\\n",
        "CXR NAD\\\n",
        "=== MEDICATIONS===\\\n",
        "Ventolin PRN\\\n",
        "LMP; Last menstrual period, Wt; Weight\") #clinical query\n",
        "\n",
        "res = client.embeddings.create(\n",
        "    input=[query],\n",
        "    model=embed_model\n",
        ")\n",
        "\n",
        "xq = res.data[0].embedding\n",
        "res = index.query(\n",
        "    namespace=\"__default__\",\n",
        "    vector=xq, \n",
        "    top_k=10, \n",
        "    include_metadata=True\n",
        ")"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "M4nHGt-GUYAz"
      },
      "source": [
        "Response Generation"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 133,
      "metadata": {
        "id": "zZRL3nGNUYa5"
      },
      "outputs": [],
      "source": [
        "contexts = [item['metadata']['text'] for item in res['matches']]\n",
        "augmented_query = \"\\n\\n---\\n\\n\".join(contexts)+\"\\n\\n-----\\n\\n\"+query"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 134,
      "metadata": {
        "id": "dZGwGH1OUbGh"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the man -\n",
            "agement of blood cholesterol: a report of the American College of Cardiol -\n",
            "ogy/American Heart Association Task Force on Clinical Practice Guidelines. \n",
            "Circulation. 2019;139:e1046–e1081.\n",
            " 3. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/\n",
            "ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, \n",
            "detection, evaluation, and management of high blood pressure in adults: a \n",
            "report of the American College of Cardiology/American Heart Association \n",
            "Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13–\n",
            "e115.\n",
            " 4. Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC guideline \n",
            "for the management of adults with congenital heart disease: a report of \n",
            "the American College of Cardiology/American Heart Association Task \n",
            "Force on Clinical Practice Guidelines. Circulation . 2019;139:e698–\n",
            "e800.\n",
            " 5. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diag-\n",
            "nosis and treatment of patients with hypertrophic cardiomyopathy: a report \n",
            "of the American College of Cardiology/American Heart Association Joint \n",
            "Committee on Clinical Practice Guidelines. Circulation. 2020;142:e558–\n",
            "e631.\n",
            " 6. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the \n",
            "management of patients with valvular heart disease: a report of the Ameri -\n",
            "can College of Cardiology/American Heart Association Joint Committee on \n",
            "Clinical Practice Guidelines. Circulation. 2021;143:e72–e227\n",
            " 7. Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI \n",
            "guideline for coronary artery revascularization: a report of the American Col-\n",
            "lege of Cardiology/American Heart Association Joint Committee on Clinical \n",
            "Practice Guidelines. Circulation. 2022;145:e18–e114.\n",
            " 8. Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/\n",
            "SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest \n",
            "pain: a report of the American College of Cardiology/American Heart \n",
            "Association Joint Committee on Clinical Practice Guidelines. Circulation. \n",
            "2021;144:e368–e454.\n",
            " 10. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guide-\n",
            "line for the management of heart failure: a report of the American College of \n",
            "Cardiology/American Heart Association Joint Committee on Clinical Prac -\n",
            "tice Guidelines. Circulation. 2022;145:e895–e1032.\n",
            " 11. Virani SS, Newby LK, Arnold SK, et al. 2023 AHA/ACC/ACCP/ASPC/\n",
            "NLA/PCNA guideline for the management of patients with chronic coro -\n",
            "nary disease: a report of the American Heart Association/American College \n",
            "of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. \n",
            "2023;148:e9–e119.\n",
            " 12. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS \n",
            "guideline for the diagnosis and management of atrial fibrillation: a report \n",
            "of the American College of Cardiology/American Heart Association Joint \n",
            "Committee on Clinical Practice Guidelines. Circulation. 2024;149:e1–e156.\n",
            " 13. Konstam MA, Kiernan MS, Bernstein D, et al. Evaluation and management \n",
            "of right-sided heart failure: a scientific statement from the American Heart \n",
            "Association. Circulation. 2018;137:e578–e622.\n",
            " 14. Mehta LS, Warnes CA, Bradley E, et al. Cardiovascular considerations in \n",
            "caring for pregnant patients: a scientific statement from the American Heart \n",
            "Association. Circulation. 2020;141:e884–e903.\n",
            " 15. Cheng XS, VanWagner LB, Costa SP, et al. Emerging evidence on coro -\n",
            "\n",
            "---\n",
            "\n",
            "Froedtert & the Medical College of Wisconsin Endocrine Surgery - Medication Guidelines Prior to Surgery  Cardiac medications (blood pressure medications): DO NOT take on the day of surgery: • Benazepril (Lotensin) • Bumetanide (Bumex) • Candesartan (Atacand) • Captopril (Capoten) • Enalapril (Vasotec) • Eprosartan (Teveten) • Fosinopril (Monopril) • Furosemide (Lasix) • Hydrochlorothiazide (HCTZ) • Iosartan (Cozaar, Hyzaar) • Irbesartan (Avapro) • Lisinopril (Prinivil, Zestril) • Metolazone (Zaroxolyn) • Olmesartan (Benicar) • Perindopril (Aceon) • Quinapril (Accupril) • Ramipril (Altace) • Spironolactone (Aldactone) • Telmisartan (Micardis) • Valsartan (Diovan) Blood thinners: Please make sure you have discussed this with your physician or surgeon before stopping these medications. • Aspirin – Stop taking 7 days before surgery • Coumadin – Stop taking 5 days before surgery • Heparin – Must be held for 12 hours prior to surgery • Antiplatelet agents (Plavix, clopidogrel, ticlopidine) – Please follow your surgeon or cardiologist’s recommendations. Diabetes medications: Insulin – Patient with insulin pumps: • Continue your basal rate ONLY\n",
            "\n",
            "---\n",
            "\n",
            "Froedtert & the Medical College of Wisconsin Endocrine Surgery - Medication Guidelines Prior to Surgery  Cardiac medications (blood pressure medications): DO NOT take on the day of surgery: • Benazepril (Lotensin) • Bumetanide (Bumex) • Candesartan (Atacand) • Captopril (Capoten) • Enalapril (Vasotec) • Eprosartan (Teveten) • Fosinopril (Monopril) • Furosemide (Lasix) • Hydrochlorothiazide (HCTZ) • Iosartan (Cozaar, Hyzaar) • Irbesartan (Avapro) • Lisinopril (Prinivil, Zestril) • Metolazone (Zaroxolyn) • Olmesartan (Benicar) • Perindopril (Aceon) • Quinapril (Accupril) • Ramipril (Altace) • Spironolactone (Aldactone) • Telmisartan (Micardis) • Valsartan (Diovan) Blood thinners: Please make sure you have discussed this with your physician or surgeon before stopping these medications. • Aspirin – Stop taking 7 days before surgery • Coumadin – Stop taking 5 days before surgery • Heparin – Must be held for 12 hours prior to surgery • Antiplatelet agents (Plavix, clopidogrel, ticlopidine) – Please follow your surgeon or cardiologist’s recommendations. Diabetes medications: Insulin – Patient with insulin pumps: • Continue your basal rate ONLY\n",
            "\n",
            "---\n",
            "\n",
            "Froedtert & the Medical College of Wisconsin Endocrine Surgery - Medication Guidelines Prior to Surgery  Cardiac medications (blood pressure medications): DO NOT take on the day of surgery: • Benazepril (Lotensin) • Bumetanide (Bumex) • Candesartan (Atacand) • Captopril (Capoten) • Enalapril (Vasotec) • Eprosartan (Teveten) • Fosinopril (Monopril) • Furosemide (Lasix) • Hydrochlorothiazide (HCTZ) • Iosartan (Cozaar, Hyzaar) • Irbesartan (Avapro) • Lisinopril (Prinivil, Zestril) • Metolazone (Zaroxolyn) • Olmesartan (Benicar) • Perindopril (Aceon) • Quinapril (Accupril) • Ramipril (Altace) • Spironolactone (Aldactone) • Telmisartan (Micardis) • Valsartan (Diovan) Blood thinners: Please make sure you have discussed this with your physician or surgeon before stopping these medications. • Aspirin – Stop taking 7 days before surgery • Coumadin – Stop taking 5 days before surgery • Heparin – Must be held for 12 hours prior to surgery • Antiplatelet agents (Plavix, clopidogrel, ticlopidine) – Please follow your surgeon or cardiologist’s recommendations. Diabetes medications: Insulin – Patient with insulin pumps: • Continue your basal rate ONLY\n",
            "\n",
            "---\n",
            "\n",
            "Froedtert & the Medical College of Wisconsin Endocrine Surgery - Medication Guidelines Prior to Surgery  Cardiac medications (blood pressure medications): DO NOT take on the day of surgery: • Benazepril (Lotensin) • Bumetanide (Bumex) • Candesartan (Atacand) • Captopril (Capoten) • Enalapril (Vasotec) • Eprosartan (Teveten) • Fosinopril (Monopril) • Furosemide (Lasix) • Hydrochlorothiazide (HCTZ) • Iosartan (Cozaar, Hyzaar) • Irbesartan (Avapro) • Lisinopril (Prinivil, Zestril) • Metolazone (Zaroxolyn) • Olmesartan (Benicar) • Perindopril (Aceon) • Quinapril (Accupril) • Ramipril (Altace) • Spironolactone (Aldactone) • Telmisartan (Micardis) • Valsartan (Diovan) Blood thinners: Please make sure you have discussed this with your physician or surgeon before stopping these medications. • Aspirin – Stop taking 7 days before surgery • Coumadin – Stop taking 5 days before surgery • Heparin – Must be held for 12 hours prior to surgery • Antiplatelet agents (Plavix, clopidogrel, ticlopidine) – Please follow your surgeon or cardiologist’s recommendations. Diabetes medications: Insulin – Patient with insulin pumps: • Continue your basal rate ONLY\n",
            "\n",
            "---\n",
            "\n",
            "CLINICAL STATEMENTS  \n",
            "AND GUIDELINES\n",
            "November 5, 2024 Circulation. 2024;150:e351–e442. DOI: 10.1161/CIR.0000000000001285e400\n",
            "Thompson et al 2024 Perioperative Cardiovascular Management for Noncardiac Surgery Guideline\n",
            "acceptable indications (eg, HF, history of CAD). Absent \n",
            "this evidence, an optimal strategy should restrict the \n",
            "use of beta blockers in patients with clear long-term or \n",
            "acute indications, initiating beta blockers at least 1 week \n",
            "before surgery, managing chronic beta blockers as ap -\n",
            "propriate to patients’ perioperative hemodynamics, and \n",
            "ensuring they are continued at discharge.\n",
            "Recommendation-Specific Supportive Text\n",
            " 1. Early studies of beta-blockade suggesting benefit \n",
            "may have produced their results by withdrawing \n",
            "beta blockers in patients who had been on them \n",
            "long term.6 Acutely discontinuing beta blockers for \n",
            "long-term indications is harmful 1,2,7 and should be \n",
            "avoided. Clinical judgment should be used to titrate \n",
            "beta blockers as appropriate during the periopera-\n",
            "tive period, with a focus on ensuring the medica -\n",
            "tion is continued through the hospital stay and at \n",
            "discharge unless clear contraindications arise.\n",
            " 2. Results from POISE indicate that initiating beta \n",
            "blockers on the day of surgery is harmful, particu -\n",
            "larly if the medication is started at higher doses. 8 \n",
            "Contemporaneous studies focused on initiating \n",
            "beta-blockade weeks in advance and titrated to \n",
            "physiological effect showed clinical benefit, but \n",
            "these results have since been called into question.9 \n",
            "A large observational study of beta-blocker initia -\n",
            "tion before NCS suggested higher risks of death \n",
            "if beta blockers were initiated <7 days before sur-\n",
            "gery3 compared with patients who initiated beta \n",
            "blockers >31 days earlier. Patients who initiated \n",
            "beta blockers between 8 and 30 days did not have \n",
            "excess mortality, nor did they show any periopera -\n",
            "tive benefits. Thus, if a patient requires initiation \n",
            "of beta blockers before surgery, the medication \n",
            "should be initiated ≥7 days before the surgery.\n",
            " 3. Initial evidence for perioperative beta blockers was \n",
            "derived from several relatively underpowered RCTs \n",
            "and a large observational study suggesting ben -\n",
            "efit from perioperative beta blockers. These were \n",
            "followed by the large multicenter POISE study, 8 \n",
            "which demonstrated mixed benefits (eg, moderate \n",
            "reduction in MACE) balanced by harms (eg, hypo -\n",
            "tension, stroke, with a net increase in all-cause \n",
            "mortality) when high-dose beta blockers were \n",
            "administered to beta blocker–naïve patients imme-\n",
            "diately before surgery and maintained throughout \n",
            "the perioperative period. 9,10 Similar to the system -\n",
            "atic review for the “2014 ACC/AHA Guideline \n",
            "on Perioperative Cardiovascular Evaluation and \n",
            "Management of Patients Undergoing Noncardiac \n",
            "Surgery,”11 this guideline excludes a group of peri-\n",
            "operative beta-blocker trials from consideration \n",
            "because of concern for unreliable data leading to \n",
            "spurious results. Evidence from 3 meta-analyses  \n",
            "was concordant regarding potential harms of \n",
            "perioperative beta-blocker administration; how -\n",
            "ever, the results of each of these studies were \n",
            "heavily influenced by the large POISE-1 sample \n",
            "size.4,11,12 Although large observational studies \n",
            "have suggested higher potential benefit of beta-\n",
            "blockade in patients at increased risk as defined \n",
            "by the RCRI, these results have not been repli -\n",
            "cated in clinical trials.13,14\n",
            "7.8. Perioperative Management of Blood \n",
            "Glucose\n",
            "Recommendations for Perioperative Management of Blood Glucose\n",
            "Referenced studies that support the recommendations are  \n",
            "summarized in the Online Data Supplement.\n",
            "COR LOE Recommendations\n",
            "2a B-NR\n",
            " 1. In patients with or at risk for diabetes who are \n",
            "scheduled for elective NCS, preoperative hemoglobin \n",
            "A1c (HbA1C) testing is reasonable if it has not been \n",
            "performed in ≤3 months.1–4\n",
            "1 C-LD\n",
            " 2. In patients scheduled for NCS, SGLT2i should be \n",
            "discontinued 3 to 4 days* days before surgery to \n",
            "reduce the risk of perioperative metabolic acidosis.5–7\n",
            "\n",
            "---\n",
            "\n",
            "3 of 11 \n",
            "OPPIC Document ID: 17346  Date of last major update:  3/03/2021       Review Date: 03/03/2024 \n",
            "Disclaimer: A printed copy of this document may be out of date. To ensure you are using the current version, \n",
            "refer to OPPIC.  \n",
            "• The procedure requires the Neuro interventionist to puncture a main artery (usually in the groin) \n",
            "and thread a \n",
            "catheter up through the arterial system into the brain circulation. A combination of high -tech \n",
            "devices (stentretrievers and suction catheters) are carefully used to manually remove the blockage \n",
            "Indications for ECR: \n",
            "Unlike with thrombolysis (where time from onset is a primary consideration for treatment eligibility) ECR \n",
            "eligibility relies \n",
            "heavily on appearance of brain imaging. Benefits of the procedure are demonstrable up to 24 hours after \n",
            "onset in \n",
            "(radiologically and clinically) select cases. Thus, all patients with a reasonable level of functional \n",
            "independence (modified \n",
            "Rankin Scale (mRS) score ≤3), within 24 hours of stroke onset, should undergo urgent ad vanced brain \n",
            "imaging (with CT \n",
            "perfusion and CT angiogram) to assist in determining ECR treatment eligibility, even if stroke \n",
            "signs/symptoms are mild \n",
            "or resolving \n",
            "The following criteria guide identification of patients who are potentially eligibility for ECR: \n",
            "1. Adult patients \n",
            "2. Reasonable degree of baseline functional independence – modified Rankin Scale (mRS) score ≤3 \n",
            "(e.g. people \n",
            "who do not have advanced dementia and who are able to shower/dress/toilet independently, \n",
            "mobilise with or \n",
            "without gait aid and assistance) \n",
            "3. Imaging confirms large vessel occlusion of any of the following large arteries; \n",
            "• Internal Carotid Artery (ICA) \n",
            "• Basilar Artery (BA) \n",
            "• Middle Cerebral Artery (MCA) – first segment (M1) or proximal portion of the second segment \n",
            "(M2) \n",
            "• Distal Vertebral Artery (VA) \n",
            "• Posterior Cerebral Artery (PCA) – proximal segment of first segment (P1) \n",
            "4. Imaging confirms mismatch between salvageable ischaemic penumbra and infarct coren \n",
            "5. Absence of extensive hypodensity on initial non-contrast CT \n",
            "Cautions and considerations for ECR: \n",
            "Careful consideration should be given to ECR eligibility decisions in the following scenarios; \n",
            "1. Paediatric patients – should be discussed urgently with Dr Mark Mackey, Paediatric Neurologist, \n",
            "Royal \n",
            "Children’s Hospital and/or Royal Melbourne Hospital Stroke Consultant on call \n",
            "2. Patients with end-stage terminal illness (i.e. currently receiving palliative care) – consider quality \n",
            "of life benefit\n",
            "\n",
            "---\n",
            "\n",
            "CLINICAL STATEMENTS \n",
            "AND GUIDELINES\n",
            "Circulation. 2024;150:e351–e442. DOI: 10.1161/CIR.0000000000001285 November 5, 2024 e429\n",
            "Thompson et al 2024 Perioperative Cardiovascular Management for Noncardiac Surgery Guideline\n",
            " 26. Majeed A, Agren A, Holmstrom M, et al. Management of rivaroxaban- or \n",
            "apixaban-associated major bleeding with prothrombin complex concen -\n",
            "trates: a cohort study. Blood. 2017;130:1706–1712.\n",
            " 27. Milling TJ Jr, Middeldorp S, Xu L, et al. Final study report of andexanet alfa \n",
            "for major bleeding with factor Xa inhibitors. Circulation. 2023;147:1026–\n",
            "1038.\n",
            " 28. Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran  \n",
            "reversal-full cohort analysis. N Engl J Med. 2017;377:431–441.\n",
            " 29. Narouze S, Benzon HT, Provenzano D, et al. Interventional spine and pain \n",
            "procedures in patients on antiplatelet and anticoagulant medications (sec -\n",
            "ond edition): guidelines from the American Society of Regional Anesthesia \n",
            "and Pain Medicine, the European Society of Regional Anaesthesia and Pain \n",
            "Therapy, the American Academy of Pain Medicine, the International Neuro-\n",
            "modulation Society, the North American Neuromodulation Society, and the \n",
            "World Institute of Pain. Reg Anesth Pain Med. 2018;43:225–262.\n",
            " 30. Schulman S, Carrier M, Lee AY, et al. Perioperative management of dabiga-\n",
            "tran: a prospective cohort study. Circulation. 2015;132:167–173.\n",
            " 31. Lip GY, Frison L, Halperin JL, et al. Comparative validation of a novel risk \n",
            "score for predicting bleeding risk in anticoagulated patients with atrial fi -\n",
            "brillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, \n",
            "Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alco-\n",
            "hol Concomitantly) score. J Am Coll Cardiol. 2011;57:173–180.\n",
            " 32. Clark NP, Douketis JD, Hasselblad V, et al. Predictors of perioperative major \n",
            "bleeding in patients who interrupt warfarin for an elective surgery or proce-\n",
            "dure: analysis of the BRIDGE trial. Am Heart J. 2018;195:108–114.\n",
            " 33. Steinberg BA, Shrader P, Pieper K, et al. Frequency and outcomes of  \n",
            "reduced dose non-vitamin K antagonist anticoagulants: results from  \n",
            "ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of \n",
            "Atrial Fibrillation II). J Am Heart Assoc. 2018;7:e007633.\n",
            " 34. Chaudhary R, Singh A, Chaudhary R, et al. Evaluation of direct oral antico -\n",
            "agulant reversal agents in intracranial hemorrhage: a systematic review and \n",
            "meta-analysis. JAMA Network Open. 2022;5:e2240145.\n",
            "7.7. Perioperative Beta Blockers\n",
            " 1. Prins KW, Neill JM, Tyler JO, et al. Effects of beta-blocker withdrawal in \n",
            "acute decompensated heart failure: a systematic review and meta-analysis. \n",
            "JACC Heart Fail. 2015;3:647–653.\n",
            " 2. Neumann A, Maura G, Weill A, et al. Clinical events after discontinuation \n",
            "of β-blockers in patients without heart failure optimally treated after acute \n",
            "myocardial infarction. Circ Cardiovasc Qual Outcomes. 2018;11:e004356.\n",
            " 3. Wijeysundera DN, Beattie WS, Wijeysundera HC, et al. Duration of preop -\n",
            "erative β-blockade and outcomes after major elective noncardiac surgery. \n",
            "Can J Cardiol. 2014;30:217–223.\n",
            " 4. Blessberger H, Lewis SR, Pritchard MW, et al. Perioperative beta-blockers\n",
            "\n",
            "---\n",
            "\n",
            "d’anesthe´sie en SOP (par ex., entre deux cas);\n",
            "• Le fait de ne jamais laisser de substances re´glemente´es\n",
            "(y compris celles pre´pare´es dans des seringues ou des\n",
            "sacs) sans surveillance, quel que soit le lieu;\n",
            "• La vidange du contenu des seringues et sacs contenant\n",
            "des substances re´glemente´es avant de les jeter;\n",
            "• L’adoption de syste `mes d’e ´limination et/ou de\n",
            "destruction pour se de ´barrasser des substances\n",
            "controˆle´es inutilise´es;\n",
            "• Une re´ﬂexion sur la possibilite ´ d’exiger que les\n",
            "substances controˆle´es inutilise´es soient retourne´es a` la\n",
            "pharmacie et soumises a` des analyses ale´atoires;\n",
            "• Des controˆles pe´riodiques des dossiers d’utilisation des\n",
            "substances re´glemente´es du personnel de soins de sante´\n",
            "et de leurs dossiers anesthe´siques; et\n",
            "• L’installation e ´ventuelle d’armoires d’anesthe ´sie\n",
            "automatise´es ou d’armoires de distribution de\n",
            "me´dicaments automatise´es (par ex. Omnicell, Pyxis).\n",
            "Par exemple, les SOP, salles d’accouchement, salles de\n",
            "re´veil et de blocs re´gionaux devraient toutes eˆtre reconnues\n",
            "comme des zones a ` risque e´leve´ de de´tournement de\n",
            "me´dicaments controˆle´s; par conse ´quent, elles devraient\n",
            "faire l’objet d’une se ´curite´, d’une surveillance et de\n",
            "controˆles accrus.\n",
            "5. En cas d’anesthe ´sie ge ´ne´rale, les syste `mes\n",
            "d’anesthe´sie e´lectroniques doivent re ´pondre a` la\n",
            "norme CAN/CSA-C22.2 No. 60601-2-13. Une autre\n",
            "me´thode de ventilation (par ex. un ballon manuel et\n",
            "un masque de re´animation) doit eˆtre a` porte´e de main\n",
            "a` coˆte´ de chaque appareil d’anesthe´sie. Les stations\n",
            "de travail doivent disposer d’au moins un analyseur\n",
            "d’oxyge`ne, un moniteur de la pression des voies\n",
            "ae´riennes, un syste `me d’e ´vacuation des gaz\n",
            "anesthe´siques re´siduels et un appareil de succion\n",
            "trache´ale puissant avec un dispositif supple ´mentaire\n",
            "de succion. En cas d’utilisation de vaporisateurs,\n",
            "ceux-ci doivent utiliser un dispositif de remplissage\n",
            "spe´ciﬁque a ` chaque agent aﬁn de garantir le\n",
            "remplissage avec le bon agent. S’il y a un\n",
            "ventilateur, il doit eˆtre muni d’une alarme de basse\n",
            "pression ou de de´connexion.\n",
            "6. Le mate´riel, les fournitures et l’aide ne´cessaires a`\n",
            "l’exe´cution se´curitaire de proce ´dures invasives\n",
            "sont disponibles. Des appareils de diagnostic, tels\n",
            "que, entre autres, les appareils d’e ´chographie et\n",
            "les ampliﬁcateurs d’image, devraient e ˆtre a` la\n",
            "disposition de l’anesthe´siologiste au besoin. Des\n",
            "dispositifs d’e´chographie de´die´s doivent eˆtre mis a`\n",
            "disposition par l’e ´tablissement pour le\n",
            "G. Dobson et al.\n",
            "123\n",
            "\n",
            "---\n",
            "\n",
            "d’anesthe´sie en SOP (par ex., entre deux cas);\n",
            "• Le fait de ne jamais laisser de substances re´glemente´es\n",
            "(y compris celles pre´pare´es dans des seringues ou des\n",
            "sacs) sans surveillance, quel que soit le lieu;\n",
            "• La vidange du contenu des seringues et sacs contenant\n",
            "des substances re´glemente´es avant de les jeter;\n",
            "• L’adoption de syste `mes d’e ´limination et/ou de\n",
            "destruction pour se de ´barrasser des substances\n",
            "controˆle´es inutilise´es;\n",
            "• Une re´ﬂexion sur la possibilite ´ d’exiger que les\n",
            "substances controˆle´es inutilise´es soient retourne´es a` la\n",
            "pharmacie et soumises a` des analyses ale´atoires;\n",
            "• Des controˆles pe´riodiques des dossiers d’utilisation des\n",
            "substances re´glemente´es du personnel de soins de sante´\n",
            "et de leurs dossiers anesthe´siques; et\n",
            "• L’installation e ´ventuelle d’armoires d’anesthe ´sie\n",
            "automatise´es ou d’armoires de distribution de\n",
            "me´dicaments automatise´es (par ex. Omnicell, Pyxis).\n",
            "Par exemple, les SOP, salles d’accouchement, salles de\n",
            "re´veil et de blocs re´gionaux devraient toutes eˆtre reconnues\n",
            "comme des zones a ` risque e´leve´ de de´tournement de\n",
            "me´dicaments controˆle´s; par conse ´quent, elles devraient\n",
            "faire l’objet d’une se ´curite´, d’une surveillance et de\n",
            "controˆles accrus.\n",
            "5. En cas d’anesthe ´sie ge ´ne´rale, les syste `mes\n",
            "d’anesthe´sie e´lectroniques doivent re ´pondre a` la\n",
            "norme CAN/CSA-C22.2 No. 60601-2-13. Une autre\n",
            "me´thode de ventilation (par ex. un ballon manuel et\n",
            "un masque de re´animation) doit eˆtre a` porte´e de main\n",
            "a` coˆte´ de chaque appareil d’anesthe´sie. Les stations\n",
            "de travail doivent disposer d’au moins un analyseur\n",
            "d’oxyge`ne, un moniteur de la pression des voies\n",
            "ae´riennes, un syste `me d’e ´vacuation des gaz\n",
            "anesthe´siques re´siduels et un appareil de succion\n",
            "trache´ale puissant avec un dispositif supple ´mentaire\n",
            "de succion. En cas d’utilisation de vaporisateurs,\n",
            "ceux-ci doivent utiliser un dispositif de remplissage\n",
            "spe´ciﬁque a ` chaque agent aﬁn de garantir le\n",
            "remplissage avec le bon agent. S’il y a un\n",
            "ventilateur, il doit eˆtre muni d’une alarme de basse\n",
            "pression ou de de´connexion.\n",
            "6. Le mate´riel, les fournitures et l’aide ne´cessaires a`\n",
            "l’exe´cution se´curitaire de proce ´dures invasives\n",
            "sont disponibles. Des appareils de diagnostic, tels\n",
            "que, entre autres, les appareils d’e ´chographie et\n",
            "les ampliﬁcateurs d’image, devraient e ˆtre a` la\n",
            "disposition de l’anesthe´siologiste au besoin. Des\n",
            "dispositifs d’e´chographie de´die´s doivent eˆtre mis a`\n",
            "disposition par l’e ´tablissement pour le\n",
            "G. Dobson et al.\n",
            "123\n",
            "\n",
            "-----\n",
            "\n",
            "38/Chinese/FemaleAllergy to aspirin, paracetamol, penicillin - rashes and itchinessExSmoker—smoked 10 years ago/Occasional DrinkerLMP: last monthWt 94.7 Ht 166.3 BMI 34.2 BP 127/81 HR 88 SpO2 100% on RAComing in for BILATERAL REVISION FESS, REVISION SEPTOPLASTY, ADENOIDECTOMY, AND BILATERAL INFERIOR TURBINOPLASTIES/SEVERE OSA ON CPAP=== PAST MEDICAL HISTORY ===1. Severe OSA on CPAP—AHI 58—CPAP settings: AutoCPAP (4–15) cmH2O, without humidifier/Chinstrap2. Right persistent Sinusitis3. Allergic rhinitis4. Adenoid hypertrophy5. High BMI6. Asthma—f/u GP, last seen 3 months ago for attack—on PRN ventolin—Does not use ventolin at all—No previous admissions/ intubations for asthma7. Diabetes—HbA1C 9.4%, Last seen outpatient doctor >1 year ago.No history of HTN/ HLD/ IHD/ CVA=== SURGICAL HISTORY===Tonsillectomy > 10 years ago mild PONV===Investigations===Hb 13.0 TW 4 Plt 392INR PT APTT normalNa 134 K3.4 Cr 77 Glu 13ECG NSRCXR NAD=== MEDICATIONS===Ventolin PRNLMP; Last menstrual period, Wt; Weight\n"
          ]
        }
      ],
      "source": [
        "print(augmented_query)"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "QQ4361Jum_rC"
      },
      "source": [
        "LLM Integration (GPT 4)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 135,
      "metadata": {
        "id": "ouifbSEOnHpK"
      },
      "outputs": [],
      "source": [
        "from openai import OpenAI\n",
        "client = OpenAI()\n",
        "\n",
        "response = client.chat.completions.create(\n",
        "  model=\"o3-mini\",\n",
        "  messages=[\n",
        "    {\"role\": \"system\", \"content\": \n",
        "     \"You are the anesthesiologist seeing this patient in the preoperative clinic 2 weeks before the date of operation. The patients have already taken their routine preoperative\\\n",
        "      investigations and the findings are listed within the clinical summary.\\\n",
        "      Your role is to evaluate the clinical summary and give the preoperative anesthesia instructions for the following patient targeted to your fellow medical colleagues. You are to\\\n",
        "      follow strictly the guidelines.\\\n",
        "      Your instructions should consist of the following components:\\\n",
        "      1. Provide a traffic light status for the surgery. If there is a risk and the patient needs to be seen by a Doctor or a Nurse, its red, if further tests are required, its yellow; if the patient is healthy and ready for surgery, its green.\\\n",
        "      2. Fasting instructions - list instructions based on the number of hours before the time of the listed surgery\\\n",
        "      3. Suitability for preoperative carbohydrate loading — yes/no.\\\n",
        "      4. Medication instructions — name each medication and give the instructions for the day of the operation and days leading up to the operation as required.\\\n",
        "      5. Any instructions for the healthcare team—for example, preoperative blood group matching, arranging for preoperative dialysis, or standby post-operative high\\\n",
        "      dependency/ICU beds.\\\n",
        "      6. Provide the RCRI, ASA, DASI and STOP-BANG scores for the patient. If you cannot calculate it, provide the extra information you need to calculate it.\\\n",
        "      Your instructions are the final instructions, explain the reasoning for your \\\n",
        "      if you are uncertain, explain what further information you require.\\\n",
        "      If the medical condition is already optimized, there is no need to offer further optimization. If there\\\n",
        "      are no relevant instructions in any of the above categories, leave it blank and write NA\"}, #System Prompt\n",
        "    {\"role\": \"user\", \"content\": augmented_query},\n",
        "  ]\n",
        ")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 136,
      "metadata": {
        "id": "vIny4TvmnU4C"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Below is the final pre‐op anesthesia recommendation for our 38‐year‐old Chinese female scheduled in 2 weeks for bilateral revision FESS, revision septoplasty, adenoidectomy, and bilateral inferior turbinoplasties.\n",
            "\n",
            "───────────────────────────── \n",
            "1. Traffic Light Status \n",
            "• Yellow – The patient’s comorbidities (severe OSA on CPAP, obesity, poorly controlled diabetes with HbA1c of 9.4%) warrant further preoperative optimization and clarification of her current diabetic regimen. Although her airway (and asthma) appear stable and her basic labs are acceptable, additional work‐up or optimization (particularly glycemic) is recommended prior to proceeding.\n",
            "\n",
            "───────────────────────────── \n",
            "2. Fasting Instructions \n",
            "• Solids: Stop eating 6 hours before the scheduled start time of surgery. \n",
            "• Clear Liquids: May be taken up to 2 hours preoperatively. \n",
            "\n",
            "───────────────────────────── \n",
            "3. Suitability for Preoperative Carbohydrate Loading \n",
            "• No – Given her poorly controlled diabetes (HbA1c 9.4% and current blood glucose of 13 mmol/L), carbohydrate loading is not recommended.\n",
            "\n",
            "───────────────────────────── \n",
            "4. Medication Instructions \n",
            "A. Cardiac/BP Medications \n",
            " – Although she is not documented as taking any antihypertensives, if she is on any such agents (e.g., ACE inhibitors or ARBs), advise that these are withheld on the morning of surgery per the endocrine surgery medication guidelines.\n",
            "B. Diabetes Medications \n",
            " – If the patient is on any oral hypoglycemic agents or SGLT2 inhibitors, please note that per current recommendations SGLT2 inhibitors should be held 3–4 days preoperatively to reduce the risk of perioperative metabolic acidosis. \n",
            " – For other diabetes medications (e.g., metformin) review her regimen with her diabetes provider; generally, metformin is held on the day of surgery if there is any concern for contrast administration or renal issues.\n",
            " – If she uses insulin and/or an insulin pump, instruct her to continue her basal rate only and adjust bolus doses as per her endocrinology team’s advice on the day of surgery.\n",
            "C. Asthma \n",
            " – Use of Ventolin (albuterol) remains with a PRN basis. Instruct the patient to bring her inhaler with her.\n",
            "D. CPAP for OSA \n",
            " – Reinforce that she should bring her CPAP machine and continue its use as prescribed preoperatively (optimally the night before and postoperatively).\n",
            "\n",
            "(If additional medications are discovered on further review of her outpatient list, please confirm adherence to the Froedtert & Medical College of Wisconsin endocrine surgery guidelines.)\n",
            "\n",
            "───────────────────────────── \n",
            "5. Instructions for the Healthcare Team \n",
            "• Alert the perioperative team to her severe obstructive sleep apnea, high BMI, and poor glycemic control; these factors may increase the risk for airway management difficulties as well as perioperative glycemic instability. \n",
            "• Ensure that her CPAP machine is available on the day of surgery.\n",
            "• Recommend that postoperative monitoring be considered in an extended recovery area or high dependency unit, particularly to monitor respiratory status and blood glucose.\n",
            "• Consider a preoperative consultation with her primary care or endocrinology team to optimize diabetic parameters prior to surgery.\n",
            "\n",
            "───────────────────────────── \n",
            "6. Risk Scores \n",
            "• Revised Cardiac Risk Index (RCRI): \n",
            " – Known diabetes is present (if she is on insulin this counts as 1 point). No other RCRI factors are reported. (Score ≈1.)\n",
            "  • Additional needed information: Clarification on whether she is insulin dependent.\n",
            "• ASA Classification: \n",
            " – Likely ASA III given her obesity, severe OSA, and poorly controlled diabetes.\n",
            "• Duke Activity Status Index (DASI): \n",
            " – Cannot be calculated without information on her functional capacity (i.e., METs or activity-specific details). Please provide details on her exercise tolerance or daily activity level.\n",
            "• STOP-BANG Score: \n",
            " – With known severe OSA, obesity (BMI 34.2), and other parameters (e.g., snoring, observed apneas) the score is expected to be high (likely ≥5). \n",
            "  • Additional needed information: Patient’s neck circumference, age, specific responses to the STOP questions (snoring, tiredness, observed apnea, and blood pressure history) would allow for precise calculation.\n",
            "\n",
            "───────────────────────────── \n",
            "Rationale Summary \n",
            "• The diabetes control (HbA1c 9.4%, blood glucose 13) and severe OSA are the main red flags that suggest additional preoperative work-up/optimization is needed. Although the ENT surgery itself is not highly invasive from a cardio‐surgical standpoint, these comorbidities can affect anesthetic management (airway, respiratory, and metabolic stability) so careful perioperative planning is essential. \n",
            "• The fasting, medication, and monitoring instructions are provided per institutional endocrine surgery and perioperative cardiovascular guidelines.\n",
            "\n",
            "Please update with any further details regarding her diabetic regimen, functional capacity (for DASI), and specifics needed to calculate the STOP-BANG score accurately. \n",
            "\n",
            "This concludes the preoperative anesthesia instruction set for this patient.\n",
            "\n",
            "───────────────────────────── \n",
            "End of Instructions\n"
          ]
        }
      ],
      "source": [
        "print(response.choices[0].message.content)"
      ]
    }
  ],
  "metadata": {
    "colab": {
      "provenance": []
    },
    "kernelspec": {
      "display_name": ".venv",
      "language": "python",
      "name": "python3"
    },
    "language_info": {
      "codemirror_mode": {
        "name": "ipython",
        "version": 3
      },
      "file_extension": ".py",
      "mimetype": "text/x-python",
      "name": "python",
      "nbconvert_exporter": "python",
      "pygments_lexer": "ipython3",
      "version": "3.13.1"
    }
  },
  "nbformat": 4,
  "nbformat_minor": 0
}
